Patients

COVID-19 & Haemoglobin Disorders: A Classification of Risk Groups & Other Considerations (2020)
Publications

COVID-19 & Haemoglobin Disorders: A Classification of Risk Groups & Other Considerations (2020)

A TIF-compiled document aiming to provide a division of risk levels for thalassaemia and SCD patients with regards to the ongoing COVID-19 pandemic.
WEEKLY UPDATE: Developing Vaccinations & Therapeutic Drugs for COVID-19
Publications

WEEKLY UPDATE: Developing Vaccinations & Therapeutic Drugs for COVID-19

All the latest updates of TIF’s Vaccinations & Therapeutic Drugs Guide for COVID-19 gathered in one single document.
FDA Grants RMAT Designation to CTX-001™ for the Treatment of Severe TDT β-Thalassaemia & SCD
Clinical News

FDA Grants RMAT Designation to CTX-001™ for the Treatment of Severe TDT β-Thalassaemia & SCD

CRISPR Therapeutics and Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX-001, an investigational, autologous, Gene Editing hematopoietic stem cell therapy, for the treatment of severe Transfusion-Dependent β-Thalassaemia (TDT) and Sickle…
TIF’s Latest Guide for the COVID-19 Pandemic is Going Public on the International Thalassaemia Day 2020
News

TIF’s Latest Guide for the COVID-19 Pandemic is Going Public on the International Thalassaemia Day 2020

As the online celebrations for the International Thalassaemia Day 2020 are at their peak, TIF decided to publish today as a gift to its worldwide patient communities a new guide entitled ”COVID-19…
Reblozyl (luspatercept-aamt) Receives Positive CHMP Opinion for the Treatment of Adults with β-Thalassaemia
Clinical News

Reblozyl (luspatercept-aamt) Receives Positive CHMP Opinion for the Treatment of Adults with β-Thalassaemia

On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product REBLOZYL, intended for the treatment of adults…
TIF’s Global Call for Solidarity & Cooperation in support of WHO
News

TIF’s Global Call for Solidarity & Cooperation in support of WHO

  TIF expresses major concerns over the announcement of the United States to suspend financial support for the World Health Organisation (WHO) until completion of a review of the organisation’s activities related…
COVID-19: TIF Releases Position Statement on the Inclusion of Thalassaemia & SCD Patients in the High-Risk Population
News

COVID-19: TIF Releases Position Statement on the Inclusion of Thalassaemia & SCD Patients in the High-Risk Population

The SARS-CoV-2 infection presents particular challenges and great risks to patients with thalassaemia and sickle cell disease (SCD) and, if their appropriate clinical management as described in International Guidelines is…
TIF and EHA Explore How COVID-19 Is Affecting Thalassemia & SCD Patients
News

TIF and EHA Explore How COVID-19 Is Affecting Thalassemia & SCD Patients

On 16 April, TIF and the European Hematology Association (EHA) successfully organised a highly interactive webinar entitled “Thalassaemia/SCD and COVID-19: Possible risks and a proposal for a patient pathway during…
NOW ONLINE: TIF’s latest Informational Guide on Developing Vaccinations & Therapeutic Drugs for COVID-19
TIF News (DE)

NOW ONLINE: TIF’s latest Informational Guide on Developing Vaccinations & Therapeutic Drugs for COVID-19

TIF has made an effort to put together a list of studies/clinical trials for treatments and vaccines about COVID-19, which is by no means exhaustive as this situation is ever-changing…
Developing Vaccinations & Therapeutic Drugs for COVID-19 (2020)
TIF Publications

Developing Vaccinations & Therapeutic Drugs for COVID-19 (2020)

TIF has compiled a list of studies/clinical trials for developing drugs and vaccines for the COVID-19 Pandemic, which is by no means exhaustive as research in this area is dramatically…
Back to top button
Close
Close